DSA-Guided Interventional Platform For NHP Research | Prisys Biotech

Prisys Biotech provides a sophisticated Digital Subtraction Angiography (DSA) technology platform specifically designed for advanced non-human primate (NHP) research. By integrating high-resolution clinical imaging with minimally invasive interventional techniques, we enable precise anatomical targeting for drug delivery and physiological monitoring, effectively bridging the gap between preclinical studies and clinical interventional medicine.

1. Precision Organ-Oriented Drug Administration

Our DSA platform allows for the selective catheterization of specific arterial and venous branches. This enables the delivery of therapeutic agents-including small molecules, biologics, and gene therapies-directly into target organs such as the brain, liver, kidneys, or heart.

• Applications: Intracerebral (ICA/MCA) delivery, hepatic artery infusion, and renal artery targeting.
• Benefit: Achieves high local concentrations while minimizing systemic exposure and potential off-target toxicity.

2. Localized Bio-sampling for Pharmacokinetics (PK)

Beyond delivery, our interventional suite supports the collection of site-specific bio-samples. By placing micro-catheters in organ-specific outflow tracts (e.g., the cerebral venous sinus), researchers can obtain direct data on local drug metabolism and organ-specific clearance.

• Benefit: Provides superior resolution of local PK/PD profiles compared to traditional systemic blood sampling.

3. Minimally Invasive Disease Modeling

We utilize DSA guidance to establish highly consistent and translatable disease models without the need for major open surgery.

• Ischemic Stroke (MCAO): Precise placement of intraluminal filaments or autologous clots under real-time visualization.
• Vascular Thrombosis: Targeted induction of clots in specific vascular beds.
• Benefit: Reduced surgical trauma, faster animal recovery, and improved data longitudinality.

• Clinical Translatability: Replicates the exact interventional procedures used in human hospitals, ensuring the route of administration (RoA) is clinically relevant.
• Targeting Efficiency: Essential for new modalities that struggle to cross biological barriers, such as the Blood-Brain Barrier (BBB).
• Enhanced 3R Compliance: Minimally invasive techniques reduce pain and distress, allowing for refined study designs and high-quality data.

Contact PRISYS Biotech

Hot Tags: dsa-guided interventional platform for nhp research | prisys biotech, research, study, monkey, gene therapy, NHP translation, preclinical pharmacology and toxicology, testing monkeys, Translational, Translational Studies, translational toxicology